布鲁顿酪氨酸激酶抑制剂依鲁替尼专利分析

Patent analysis of Bruton′s tyrosine kinase inhibitor ibrutinib

分析依鲁替尼全球专利布局、重点主题专利布局、原研公司关于依鲁替尼的专利布局,为国内相关制药企业了解该药专利状况,进而选择决定研发突破点和市场竞争策略提供参考。本文以药物名称、药物结构为关键词,检索了中国专利文摘数据库CNABS和德温特世界专利数据库DWPI,并与国际联机检索系统STN检索结果合并去重,再选择以依鲁替尼为发明点的专利进行分析。美国Pharmacyclics公司关于依鲁替尼在中国已申请了26项专利,主题涉及化合物、组合物、新用途、剂型、制备方法等;其中已授权4项,驳回或逾期视撤8项,仍有14项专利申请处于实审中。为突破依鲁替尼的专利壁垒,中国制药企业应时刻关注和跟踪原研公司的专利审批过程和到期动态,充分利用知识产权制度对自己的创新成果进行有效保护。

The aim of this paper is to analyze the global patent layout of ibrutinib,the patent layout of key themes,and the original research company′s patent layout of ibrutinib,so as to provide a reference for the related domestic drug companies to be acquainted with the patent status of the drug,and to select and decide their breakthrough points and market competition strategies.In this study,the drug name and drug structure were used as keywords for search in the patent databases CNABS and DWPI,and the results were combined with the search results from the International Online Search System STN.Then,the patent with ibrutinib as the invention point was selected and used for further analysis.Pharmacyclics has applied for 26 patents on ibrutinib in China,and the subject matter relates to compounds,compositions,new uses,dosage forms,preparation methods and so on.Among them,4 patents have been granted,8 patents have been rejected or overdue,and 14 patent applications are still pending.In order to break through the patent barriers of ibrutinib,Chinese pharmaceutical companies should always pay much attention to the patent approval process and the expiration status of patents from the original research company,and make full use of the intellectual property system to effectively protect their own innovations.